(CRON) Cronos - Ratings and Ratios

Exchange: NASDAQ • Country: Canada • Currency: USD • Type: Common Stock • ISIN: CA22717L1013

CRON: Cannabis, Oils, Vaporizers, Edibles, Tinctures, Pre-rolls, Flower

Cronos Group Inc. (NASDAQ:CRON), a prominent player in the cannabinoid industry, specializes in the cultivation, production, and distribution of cannabis products. With operations in Canada, Israel, and Germany, the company has established a strong presence in key markets. Its product portfolio includes a variety of offerings such as dried flower, pre-rolls, oils, vaporizers, edibles, and tinctures, marketed under well-known brands like Spinach, Lord Jones, and PEACE NATURALS. Established in 2012 and headquartered in Toronto, Cronos Group has grown to become a significant entity in the cannabis sector, leveraging strategic partnerships and distribution channels to enhance its market reach.

The companys strategic focus extends to research and development, aiming to innovate in cultivation techniques and product development. This commitment to R&D underscores Cronos Groups efforts to maintain a competitive edge in a rapidly evolving industry. Additionally, their robust online presence and strategic retail partnerships play a crucial role in their market strategy, facilitating access to a broader consumer base.

Cronos Groups financial metrics reveal a mixed outlook. With a market capitalization of $753.12 million, the companys P/E and Forward P/E ratios stand at 0.00, indicating current non-profitability. The price-to-book ratio of 0.70 suggests the stock may be undervalued relative to its book value. The P/S ratio of 6.77, while high, aligns with industry standards for emerging markets like cannabis, reflecting market expectations for future growth.

Looking ahead, Cronos Groups future prospects hinge on several factors. The companys high P/S ratio may signal anticipated growth, typical in emerging industries. The negative RoE of -4.50% and zero P/E ratio suggest Cronos is in a growth phase, with significant investments likely impacting current profitability. A P/B ratio below 1 may indicate market caution regarding asset

Additional Sources for CRON Stock

CRON Stock Overview

Market Cap in USD 769m
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
GiC Sub-Industry Pharmaceuticals
IPO / Inception 2016-07-12

CRON Stock Ratings

Growth 5y -81.1%
Fundamental 10.5%
Dividend 0.0%
Rel. Strength Industry -5.38
Analysts 3.4/5
Fair Price Momentum 1.46 USD
Fair Price DCF 0.22 USD

CRON Dividends

No Dividends Paid

CRON Growth Ratios

Growth Correlation 3m -12.4%
Growth Correlation 12m -90.3%
Growth Correlation 5y -84.5%
CAGR 5y -18.88%
CAGR/Max DD 5y -0.21
Sharpe Ratio 12m -2.40
Alpha -15.19
Beta 0.99
Volatility 47.41%
Current Volume 1095.8k
Average Volume 20d 1551.8k
What is the price of CRON stocks?
As of March 15, 2025, the stock is trading at USD 1.89 with a total of 1,095,755 shares traded.
Over the past week, the price has changed by -5.03%, over one month by -4.06%, over three months by -2.07% and over the past year by -4.55%.
Is Cronos a good stock to buy?
Neither. Based on ValueRay Fundamental Analyses, Cronos is currently (March 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of 10.47 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of CRON as of March 2025 is 1.46. This means that CRON is currently overvalued and has a potential downside of -22.75%.
Is CRON a buy, sell or hold?
Cronos has received a consensus analysts rating of 3.40. Therefor, it is recommend to hold CRON.
  • Strong Buy: 1
  • Buy: 1
  • Hold: 2
  • Sell: 1
  • Strong Sell: 0
What are the forecast for CRON stock price target?
According to ValueRays Forecast Model, CRON Cronos will be worth about 1.6 in March 2026. The stock is currently trading at 1.89. This means that the stock has a potential downside of -14.29%.
Issuer Forecast Upside
Wallstreet Target Price 2.1 9.5%
Analysts Target Price 2 6.9%
ValueRay Target Price 1.6 -14.3%